LP 10152Alternative Names: LP10152
Latest Information Update: 21 Jan 2010
At a glance
- Originator Eli Lilly
- Mechanism of Action Fibroblast growth factor 21 agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 26 Mar 2009 Clinical development of LP 10152 is ongoing in USA
- 31 Dec 2007 Phase-I/II clinical trials in Type-2 diabetes mellitus in USA (unspecified route)